Moneycontrol PRO
HomeNewsBusinessCompaniesCoronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet

Coronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.

August 04, 2020 / 16:22 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Sun Pharma on August 4 said it has launched Favipiravir 200 mg under brand name FluGuard at a price of Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.

    Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.

    At Rs 35 per tablet, Sun Pharma's Favipiravir version would be the cheapest in the market.

    The DCGI has approved Favipiravir versions of half a dozen companies including Glenmark, Cipla, Hetero, Brinton Pharmaceuticals and Jenburkt, despite clinical trial data from Glenmark not being statistically significant.

    COVID-19 Vaccine

    Frequently Asked Questions

    View more
    How does a vaccine work?

    A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

    How many types of vaccines are there?

    There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

    What does it take to develop a vaccine of this kind?

    Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

    View more
    Show

    Dr Reddy’s had earlier signed with the innovator company Fujifilm to sell the drug.

    “With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals," said Kirti Ganorkar, CEO of India Business of Sun Pharma, said.

    "We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response," Ganorkar said.

    The company said it will work closely with the government and medical community to ensure availability of FluGuard to patients across the country.

    The stocks of FluGuard will be available in the market from this week.

    Viswanath Pilla
    Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
    first published: Aug 4, 2020 04:21 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347